{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:08:30Z","timestamp":1790791710677,"version":"4.1.0"},"reference-count":229,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016867","name":"ZOLL Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016867","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DNA"],"abstract":"<jats:p>CRISPR-based transcriptional regulation technologies, including CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi), offer precise and programmable control over gene expression, representing a major advance in gene and epigenetic therapy. CRISPRa uses nuclease-inactive Cas proteins fused to transcriptional activators to upregulate target genes, while CRISPRi employs repressor domains for gene silencing. Preclinical studies have demonstrated the efficacy of CRISPRa\/i in models of metabolic, neurological, muscular, and oncological diseases. Notably, CRISPRi-based therapies have entered clinical trials for conditions like hepatitis B and muscular dystrophy, showing encouraging safety and efficacy profiles. Despite ongoing challenges related to delivery efficiency, immunogenicity, and off-target activity, innovations in protein engineering and guide RNA design are rapidly enhancing the precision and safety of these technologies. Overall, CRISPRa and CRISPRi are poised to transform the treatment of genetic and epigenetic disorders, with continued optimization expected to accelerate their clinical adoption and broaden their therapeutic impact.<\/jats:p>","DOI":"10.3390\/dna5040057","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:37:02Z","timestamp":1764952622000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CRISPR-Based Transcriptional Regulation: Technologies, Applications, and Future Directions"],"prefix":"10.3390","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4843-6136","authenticated-orcid":false,"given":"Mira A.","family":"Srinivasa","sequence":"first","affiliation":[{"name":"Department of Bioengineering, Rice University, Houston, TX 77005, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2262-7800","authenticated-orcid":false,"given":"Mario","family":"Escobar","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Rice University, Houston, TX 77005, USA"},{"name":"Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, Present, and Future of CRISPR Genome Editing Technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","article-title":"CRISPR\/Cas9 Therapeutics: Progress and Prospects","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"eadd8643","DOI":"10.1126\/science.add8643","article-title":"CRISPR Technology: A Decade of Genome Editing Is Only the Beginning","volume":"379","author":"Wang","year":"2023","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome Engineering Using the CRISPR-Cas9 System","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"E2579","DOI":"10.1073\/pnas.1208507109","article-title":"Cas9\u2013crRNA Ribonucleoprotein Complex Mediates Specific DNA Cleavage for Adaptive Immunity in Bacteria","volume":"109","author":"Gasiunas","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 Structures and Mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1590\/S1807-59322009000800016","article-title":"A Review of Blood Substitutes: Examining the History, Clinical Trial Results, and Ethics of Hemoglobin-Based Oxygen Carriers","volume":"64","author":"Chen","year":"2009","journal-title":"Clinics"},{"key":"ref_9","first-page":"353","article-title":"Mechanism and Applications of CRISPR\/Cas-9-Mediated Genome Editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev.biochem.052308.093131","article-title":"The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway","volume":"79","author":"Lieber","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/cr.2013.45","article-title":"Genome Editing with RNA-Guided Cas9 Nuclease in Zebrafish Embryos","volume":"23","author":"Chang","year":"2013","journal-title":"Cell Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1007\/s00018-019-03396-8","article-title":"Cas12a Mediates Efficient and Precise Endogenous Gene Tagging via MITI: Microhomology-Dependent Targeted Integrations","volume":"77","author":"Li","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12033-021-00422-8","article-title":"CRISPR\/Cas-Based Modifications for Therapeutic Applications: A Review","volume":"64","author":"Bharathkumar","year":"2022","journal-title":"Mol. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"pgaf168","DOI":"10.1093\/pnasnexus\/pgaf168","article-title":"Gene Therapy for Ocular Hypertension Using hfCas13d-Mediated mRNA Targeting","volume":"4","author":"Chen","year":"2025","journal-title":"PNAS Nexus"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Huang, Z., Fang, J., Zhou, M., Gong, Z., and Xiang, T. (2022). CRISPR-Cas13: A New Technology for the Rapid Detection of Pathogenic Microorganisms. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.1011399"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20969","DOI":"10.1073\/pnas.1906843116","article-title":"Rationally Engineered Staphylococcus aureus Cas9 Nucleases with High Genome-Wide Specificity","volume":"116","author":"Tan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In Vivo Genome Editing with a Small Cas9 Orthologue Derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/mt.2016.8","article-title":"Streptococcus thermophilus CRISPR-Cas9 Systems Enable Specific Editing of the Human Genome","volume":"24","author":"Lee","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, W., Zhu, J.-K., and Jin, W. (2024). A Catalog of Gene Editing Sites and Genetic Variations in Editing Sites in Model Organisms. BMC Genom., 25.","DOI":"10.1186\/s12864-024-11073-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41422-018-0131-6","article-title":"Structural Insights into a High Fidelity Variant of SpCas9","volume":"29","author":"Guo","year":"2019","journal-title":"Cell Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/nature16526","article-title":"High-Fidelity CRISPR\u2013Cas9 Nucleases with No Detectable Genome-Wide off-Target Effects","volume":"529","author":"Kleinstiver","year":"2016","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41579-019-0299-x","article-title":"Evolutionary Classification of CRISPR\u2013Cas Systems: A Burst of Class 2 and Derived Variants","volume":"18","author":"Makarova","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.molcel.2021.12.002","article-title":"The CRISPR-Cas Toolbox and Gene Editing Technologies","volume":"82","author":"Liu","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1021\/acssynbio.2c00156","article-title":"Quantification of Genome Editing and Transcriptional Control Capabilities Reveals Hierarchies among Diverse CRISPR\/Cas Systems in Human Cells","volume":"11","author":"Escobar","year":"2022","journal-title":"ACS Synth. Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary Breakthrough: FDA Approves CASGEVY, the First CRISPR\/Cas9 Gene Therapy for Sickle Cell Disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_26","unstructured":"Vor Biopharma (2025, June 13). A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients with Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation; Clinical Trial Registration NCT04849910, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04849910."},{"key":"ref_27","unstructured":"Wave Life Sciences Ltd. (2025, June 13). A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 1b\/2a Study of WVE-004 Administered Intrathecally to Patients with C9orf72-Associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD); Clinical Trial Registration NCT04931862, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04931862."},{"key":"ref_28","unstructured":"Wave Life Sciences Ltd. (2025, August 25). A Multicenter, Randomized, Double-Blind, Placebo Controlled, Phase 1b\/2a Study of WVE-003 Administered Intrathecally in Patients with Huntington\u2019s Disease (SELECT-HD); Clinical Trial Registration NCT05032196, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05032196."},{"key":"ref_29","unstructured":"Vertex Pharmaceuticals Incorporated (2025, June 13). A Phase 1\/2\/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects with Transfusion-Dependent \u03b2-Thalassemia; Clinical Trial Registration NCT03655678, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03655678."},{"key":"ref_30","unstructured":"CRISPR Therapeutics AG (2025, June 13). An Open-Label, First-in-Human Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects with Type 1 Diabetes Mellitus (T1D); Clinical Trial Registration NCT05565248, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05565248."},{"key":"ref_31","unstructured":"Intellia Therapeutics (2025, June 13). HAELO: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2002 in Participants with Hereditary Angioedema (HAE); Clinical Trial Registration NCT06634420, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06634420."},{"key":"ref_32","unstructured":"Spuler, S. (2025, June 13). Phase 1\/2a First-in-Human Trial Evaluating Autologous Gene-Edited Muscle Stem Cells in Limb Girdle Muscular Dystrophies (GenPHSats-bASKet); Clinical Trial Registration NCT05588401, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05588401."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2025.10","article-title":"Advancing CRISPR Genome Editing into Gene Therapy Clinical Trials: Progress and Future Prospects","volume":"27","author":"Cetin","year":"2025","journal-title":"Expert. Rev. Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"New Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_36","unstructured":"Beam Therapeutics Inc. (2025, July 04). A Phase 1\/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and\/or Liver Disease; Clinical Trial Registration NCT06389877, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06389877."},{"key":"ref_37","unstructured":"(2025, July 04). A Phase 1 Study of Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed\/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LLy); Clinical Trial Registration NCT06934382, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06934382."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"A4139206","DOI":"10.1161\/circ.150.suppl_1.4139206","article-title":"Abstract 4139206: Design of Heart-2: A Phase 1b Clinical Trial of VERVE-102, an in Vivo Base Editing Medicine Delivered by a GalNAc-LNP and Targeting PCSK9 to Durably Lower LDL Cholesterol","volume":"150","author":"Vafai","year":"2024","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nmeth.2598","article-title":"CRISPR RNA\u2013Guided Activation of Endogenous Human Genes","volume":"10","author":"Maeder","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nmeth.2600","article-title":"RNA-Guided Gene Activation by CRISPR-Cas9\u2013Based Transcription Factors","volume":"10","author":"Kocak","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Li, J., Li, L., Cai, S., Song, K., and Hu, S. (2024). Identification of Novel Risk Genes for Alzheimer\u2019s Disease by Integrating Genetics from Hippocampus. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-78181-0"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Zhu, R., Zhao, Y., Yin, H., Shu, L., Ma, Y., and Tao, Y. (2024). Identification of Immune-Related Hub Genes and Potential Molecular Mechanisms Involved in COVID-19 via Integrated Bioinformatics Analysis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-81803-2"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.omtn.2022.12.016","article-title":"Modulating the Expression of Tumor Suppressor Genes Using Activating Oligonucleotide Technologies as a Therapeutic Approach in Cancer","volume":"31","author":"Gregory","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal Enzyme Replacement Therapies: Historical Development, Clinical Outcomes, and Future Perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 Trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral Gene Therapy for Cerebral Adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"New Engl. J. Med."},{"key":"ref_50","unstructured":"Bluebird Bio (2025, June 14). A Phase 3 Study of Lenti-D Drug Product After Myeloablative Conditioning Using Busulfan and Fludarabine in Subjects \u226417 Years of Age with Cerebral Adrenoleukodystrophy (CALD); Clinical Trial Registration NCT03852498, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03852498."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.stemcr.2019.02.010","article-title":"Genome-Scale CRISPRa Screen Identifies Novel Factors for Cellular Reprogramming","volume":"12","author":"Yang","year":"2019","journal-title":"Stem Cell Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2014.09.039","article-title":"A Protein Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging","volume":"159","author":"Tanenbaum","year":"2014","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/cr.2013.122","article-title":"Multiplexed Activation of Endogenous Genes by CRISPR-on, an RNA-Guided Transcriptional Activator System","volume":"23","author":"Cheng","year":"2013","journal-title":"Cell Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly Efficient Cas9-Mediated Transcriptional Programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome Editing by a CRISPR-Cas9-Based Acetyltransferase Activates Genes from Promoters and Enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e2204259119","DOI":"10.1073\/pnas.2204259119","article-title":"Decorating Chromatin for Enhanced Genome Editing Using CRISPR-Cas9","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.1038\/ncomms12284","article-title":"Writing of H3K4Me3 Overcomes Epigenetic Silencing in a Sustained but Context-Dependent Manner","volume":"7","author":"Gjaltema","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cell.2016.08.056","article-title":"Editing DNA Methylation in the Mammalian Genome","volume":"167","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1038\/s41467-018-05766-5","article-title":"High-Fidelity CRISPR\/Cas9- Based Gene-Specific Hydroxymethylation Rescues Gene Expression and Attenuates Renal Fibrosis","volume":"9","author":"Xu","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.stemcr.2014.09.013","article-title":"A CRISPR\/Cas9-Based System for Reprogramming Cell Lineage Specification","volume":"3","author":"Chakraborty","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Omachi, K., and Miner, J.H. (2022). Comparative Analysis of dCas9-VP64 Variants and Multiplexed Guide RNAs Mediating CRISPR Activation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270008"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-Scale Transcriptional Activation by an Engineered CRISPR-Cas9 Complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"100387","DOI":"10.1016\/j.xgen.2023.100387","article-title":"Optimization of Cas12a for Multiplexed Genome-Scale Transcriptional Activation","volume":"3","author":"Griffith","year":"2023","journal-title":"Cell Genom."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/s41592-019-0508-6","article-title":"Multiplexed Genome Engineering by Cas12a and CRISPR Arrays Encoded on Single Transcripts","volume":"16","author":"Campa","year":"2019","journal-title":"Nat. Methods"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/nmeth.4483","article-title":"Inducible and Multiplex Gene Regulation Using CRISPR-Cpf1-Based Transcription Factors","volume":"14","author":"Tak","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e66406","DOI":"10.7554\/eLife.66406","article-title":"Enhanced Cas12a Multi-Gene Regulation Using a CRISPR Array Separator","volume":"10","author":"Magnusson","year":"2021","journal-title":"eLife"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1093\/nar\/gkad010","article-title":"Enhancement of Protein Translation by CRISPR\/dCasRx Coupled with SINEB2 Repeat of Noncoding RNAs","volume":"51","author":"Cao","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Montagud-Mart\u00ednez, R., M\u00e1rquez-Costa, R., Heras-Hern\u00e1ndez, M., Dolcemascolo, R., and Rodrigo, G. (2024). On the Ever-growing Functional Versatility of the CRISPR-Cas13 System. Microb. Biotechnol., 17.","DOI":"10.1111\/1751-7915.14418"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2309234","DOI":"10.1002\/advs.202309234","article-title":"Development and Application of the CRISPR-Dcas13d-eIF4G Translational Regulatory System to Inhibit Ferroptosis in Calcium Oxalate Crystal-Induced Kidney Injury","volume":"11","author":"He","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1093\/nar\/gkaa269","article-title":"Targeted mRNA Demethylation Using an Engineered dCas13b-ALKBH5 Fusion Protein","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Yu, J., Jin, J., Kwon, E., Jang, H., Choi, S.-K., Kim, D., Kim, C., Son, S., Yoon, K.-J., and Heo, W.D. (2025). Programmable RNA Acetylation with CRISPR-Cas13. Nat. Chem. Biol.","DOI":"10.1038\/s41589-025-01922-3"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Torkzaban, B., Kawalerski, R., and Coller, J. (2022). Development of a Tethered mRNA Amplifier to Increase Protein Expression. Biotechnol. J., 17.","DOI":"10.1002\/biot.202200214"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA Editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41593-017-0060-6","article-title":"In Vivo Simultaneous Transcriptional Activation of Multiple Genes in the Brain Using CRISPR\u2013dCas9-Activator Transgenic Mice","volume":"21","author":"Zhou","year":"2018","journal-title":"Nat. Neurosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/s41592-023-02036-1","article-title":"Compact Engineered Human Mechanosensitive Transactivation Modules Enable Potent and Versatile Synthetic Transcriptional Control","volume":"20","author":"Mahata","year":"2023","journal-title":"Nat. Methods"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e1326","DOI":"10.1002\/ctm2.1326","article-title":"CRISPRa-based Activation of Fgf21 and Fndc5 Ameliorates Obesity by Promoting Adipocytes Browning","volume":"13","author":"Zhu","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2252516","DOI":"10.1155\/2022\/2252516","article-title":"Obesity, Adipose Tissue, and Inflammation Answered in Questions","volume":"2022","author":"Guerreiro","year":"2022","journal-title":"J. Obes."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eaaz8664","DOI":"10.1126\/scitranslmed.aaz8664","article-title":"CRISPR-Engineered Human Brown-like Adipocytes Prevent Diet-Induced Obesity and Ameliorate Metabolic Syndrome in Mice","volume":"12","author":"Wang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"eaau0629","DOI":"10.1126\/science.aau0629","article-title":"CRISPR-Mediated Activation of a Promoter or Enhancer Rescues Obesity Caused by Haploinsufficiency","volume":"363","author":"Matharu","year":"2019","journal-title":"Science"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41434-023-00414-0","article-title":"CRISPR\/sgRNA-Directed Synergistic Activation Mediator (SAM) as a Therapeutic Tool for Parkinson\u00b4s Disease","volume":"31","author":"Segovia","year":"2024","journal-title":"Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e14797","DOI":"10.15252\/emmm.202114797","article-title":"Parkinson\u2019s Disease Motor Symptoms Rescue by CRISPRa-reprogramming Astrocytes into GABAergic Neurons","volume":"14","author":"Giesert","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Park, H., Hwang, Y., and Kim, J. (2021). Transcriptional Activation with Cas9 Activator Nanocomplexes Rescues Alzheimer\u2019s Disease Pathology. Biomaterials, 279.","DOI":"10.1016\/j.biomaterials.2021.121229"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI20864","article-title":"A Disintegrin-Metalloproteinase Prevents Amyloid Plaque Formation and Hippocampal Defects in an Alzheimer Disease Mouse Model","volume":"113","author":"Postina","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e12787","DOI":"10.1111\/jpi.12787","article-title":"Activation of Melatonin Receptor 1 by CRISPR-Cas9 Activator Ameliorates Cognitive Deficits in an Alzheimer\u2019s Disease Mouse Model","volume":"72","author":"Park","year":"2022","journal-title":"J. Pineal Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ana.26656","article-title":"CRISPR-Based KCC2 Upregulation Attenuates Drug-Resistant Seizure in Mouse Models of Epilepsy","volume":"94","author":"Shi","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/brain\/awaa045","article-title":"In Vivo CRISPRa Decreases Seizures and Rescues Cognitive Deficits in a Rodent Model of Epilepsy","volume":"143","author":"Colasante","year":"2020","journal-title":"Brain"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"eabn2748","DOI":"10.1126\/sciadv.abn2748","article-title":"Targeted Epigenomic Editing Ameliorates Adult Anxiety and Excessive Drinking after Adolescent Alcohol Exposure","volume":"8","author":"Bohnsack","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1016\/j.ymthe.2024.08.016","article-title":"On RNA-Programmable Gene Modulation as a Versatile Set of Principles Targeting Muscular Dystrophies","volume":"32","author":"Capelletti","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/s41467-025-57831-5","article-title":"Activation of Endogenous Full-Length Utrophin by MyoAAV-UA as a Therapeutic Approach for Duchenne Muscular Dystrophy","volume":"16","author":"Wu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-019-1430-x","article-title":"A Mutation-Independent Approach for Muscular Dystrophy via Upregulation of a Modifier Gene","volume":"572","author":"Kemaladewi","year":"2019","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jgg.2024.05.005","article-title":"Lama1 Upregulation Prolongs the Lifespan of the dyH\/dyH Mouse Model of LAMA2-Related Congenital Muscular Dystrophy","volume":"51","author":"Liu","year":"2024","journal-title":"J. Genet. Genom."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"104010","DOI":"10.1016\/j.mcn.2025.104010","article-title":"RNA-Based Therapies for Neurodegenerative Disease: Targeting Molecular Mechanisms for Disease Modification","volume":"133","author":"Bhati","year":"2025","journal-title":"Mol. Cell Neurosci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"177441","DOI":"10.1016\/j.ejphar.2025.177441","article-title":"siRNA-Based Delivery Systems: Technologies, Carriers, Applications, and Approved Products","volume":"996","author":"Ghasemiyeh","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Singh, J., Saeedan, A.S., Kaithwas, G., and Ansari, M.N. (2025). Small Interfering RNA: From Designing to Therapeutic in Cancer. J. Genet. Eng. Biotechnol., 23.","DOI":"10.1016\/j.jgeb.2025.100484"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"112993","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to Address the Challenges Facing Small Molecule Inhibitors","volume":"210","author":"Xiao","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The Current Landscape of Nucleic Acid Therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., and Bahal, R. (2020). Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med., 9.","DOI":"10.3390\/jcm9062004"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Collotta, D., Bertocchi, I., Chiapello, E., and Collino, M. (2023). Antisense Oligonucleotides: A Novel Frontier in Pharmacological Strategy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1304342"},{"key":"ref_100","unstructured":"Padda, I.S., Mahtani, A.U., Patel, P., and Parmar, M. (2025, July 07). Small Interfering RNA (siRNA) Therapy, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK580472\/."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1093\/nar\/gky437","article-title":"Specificity of RNAi, LNA and CRISPRi as Loss-of-Function Methods in Transcriptional Analysis","volume":"46","author":"Stojic","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly Specific Epigenome Editing by CRISPR-Cas9 Repressors for Silencing of Distal Regulatory Elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/nn.4347","article-title":"Histone Deacetylase 3 Associates with MeCP2 to Regulate FOXO and Social Behavior","volume":"19","author":"Nott","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41592-018-0048-5","article-title":"An Enhanced CRISPR Repressor for Targeted Mammalian Gene Regulation","volume":"15","author":"Yeo","year":"2018","journal-title":"Nat. Methods"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41592-020-0966-x","article-title":"An Efficient KRAB Domain for CRISPRi Applications in Human Cells","volume":"17","author":"Alerasool","year":"2020","journal-title":"Nat. Methods"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kristof, A., Karunakaran, K., Allen, C., Mizote, P., Briggs, S., Jian, Z., Nash, P., and Blazeck, J. (2025). Engineering Novel CRISPRi Repressors for Highly Efficient Mammalian Gene Regulation. Genome Biol., 26.","DOI":"10.1186\/s13059-025-03640-4"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-Wide Programmable Transcriptional Memory by CRISPR-Based Epigenome Editing","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1093\/nar\/gkw159","article-title":"Repurposing the CRISPR-Cas9 System for Targeted DNA Methylation","volume":"44","author":"Vojta","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"giy011","DOI":"10.1093\/gigascience\/giy011","article-title":"Genome-Wide Determination of on-Target and off-Target Characteristics for RNA-Guided DNA Methylation by dCas9 Methyltransferases","volume":"7","author":"Lin","year":"2018","journal-title":"Gigascience"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41421-019-0090-1","article-title":"Reprogrammable CRISPR\/dCas9-Based Recruitment of DNMT1 for Site-Specific DNA Demethylation and Gene Regulation","volume":"5","author":"Lu","year":"2019","journal-title":"Cell Discov."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"D901","DOI":"10.1093\/nar\/gkae1039","article-title":"CRISPRepi: A Multi-Omic Atlas for CRISPR-Based Epigenome Editing","volume":"53","author":"Shi","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1093\/nar\/gkab529","article-title":"Efficient Multiplexed Gene Regulation in Saccharomyces Cerevisiae Using dCas12a","volume":"49","author":"Ciurkot","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41587-024-02224-0","article-title":"Engineered CRISPR-Cas12a for Higher-Order Combinatorial Chromatin Perturbations","volume":"43","author":"Hsiung","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8986","DOI":"10.1093\/nar\/gkac680","article-title":"CRISPR-RNAa: Targeted Activation of Translation Using dCas13 Fusions to Translation Initiation Factors","volume":"50","author":"Otoupal","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/15476286.2024.2351657","article-title":"Programmable RNA Targeting with CRISPR-Cas13","volume":"21","author":"Shi","year":"2024","journal-title":"RNA Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/s41467-024-46412-7","article-title":"dCas13-Mediated Translational Repression for Accurate Gene Silencing in Mammalian Cells","volume":"15","author":"Apostolopoulos","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1021\/acssynbio.3c00287","article-title":"Precise Interference of RNA\u2013Protein Interaction by CRISPR-Cas13-Mediated Peptide Competition","volume":"12","author":"Li","year":"2023","journal-title":"ACS Synth. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1093\/nar\/gkae275","article-title":"CRISPR-Cas Tools for Simultaneous Transcription & Translation Control in Bacteria","volume":"52","author":"Cardiff","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/nar\/gkae110","article-title":"Programmable RNA 5-Methylcytosine (m5C) Modification of Cellular RNAs by dCasRx Conjugated Methyltransferase and Demethylase","volume":"52","author":"Zhang","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20892\/j.issn.2095-3941.2019.0325","article-title":"CRISPR-Cas13a System: A Novel Approach to Precision Oncology","volume":"17","author":"Zhang","year":"2020","journal-title":"Cancer Biol. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cels.2017.08.011","article-title":"Multiplex Enhancer Interference Reveals Collaborative Control of Gene Regulation by Estrogen Receptor \u03b1-Bound Enhancers","volume":"5","author":"Carleton","year":"2017","journal-title":"Cell Syst."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1242\/bio.019067","article-title":"Reprogrammable CRISPR\/Cas9-Based System for Inducing Site-Specific DNA Methylation","volume":"5","author":"McDonald","year":"2016","journal-title":"Biol. Open"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/nar\/gkw1112","article-title":"Efficient Targeted DNA Methylation with Chimeric dCas9\u2013Dnmt3a\u2013Dnmt3L Methyltransferase","volume":"45","author":"Stepper","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1134478","DOI":"10.3389\/fendo.2023.1134478","article-title":"EpiCRISPR Targeted Methylation of Arx Gene Initiates Transient Switch of Mouse Pancreatic Alpha to Insulin-Producing Cells","volume":"14","author":"Stepper","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41556-022-00870-7","article-title":"Multiplexed Genome Regulation in Vivo with Hyper-Efficient Cas12a","volume":"24","author":"Guo","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12943-022-01703-9","article-title":"Tumor-Secreted Exosomal miR-141 Activates Tumor-Stroma Interactions and Controls Premetastatic Niche Formation in Ovarian Cancer Metastasis","volume":"22","author":"Mo","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2203082","DOI":"10.1002\/adhm.202203082","article-title":"High-Performance Delivery of a CRISPR Interference System via Lipid-Polymer Hybrid Nanoparticles Combined with Ultrasound-Mediated Microbubble Destruction for Tumor-Specific Gene Repression","volume":"12","author":"Li","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1618","article-title":"Therapeutic Silencing of miR-10b Inhibits Metastasis in a Mouse Mammary Tumor Model","volume":"28","author":"Ma","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.18632\/oncotarget.28641","article-title":"Inhibition of miR-10b Treats Metastatic Breast Cancer by Targeting Stem Cell-like Properties","volume":"15","author":"Halim","year":"2024","journal-title":"Oncotarget"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e13084","DOI":"10.1200\/JCO.2023.41.16_suppl.e13084","article-title":"Exploring the Effects of Inhibiting miR-10b on Breast Cancer Stemness and Metastasis","volume":"41","author":"Halim","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1158\/0008-5472.CAN-15-0888","article-title":"Combining miR-10b\u2013Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer","volume":"75","author":"Yoo","year":"2015","journal-title":"Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2301310","DOI":"10.1002\/smtd.202301310","article-title":"An Inducible CRISPR-dCas9-Based Transcriptional Repression System for Cancer Therapy","volume":"8","author":"Gu","year":"2024","journal-title":"Small Methods"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Sastre, D., Zafar, F., Torres, C.A.M., Piper, D., Kirik, D., Sanders, L.H., Qi, L.S., and Sch\u00fcle, B. (2023). Inactive S. Aureus Cas9 Downregulates Alpha-Synuclein and Reduces mtDNA Damage and Oxidative Stress Levels in Human Stem Cell Model of Parkinson\u2019s Disease. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-45078-3"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1021\/acsnano.3c05864","article-title":"Ultrasound-Assisted CRISPRi-Exosome for Epigenetic Modification of \u03b1-Synuclein Gene in a Mouse Model of Parkinson\u2019s Disease","volume":"18","author":"Kong","year":"2024","journal-title":"ACS Nano"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","article-title":"Downregulation of SNCA Expression by Targeted Editing of DNA Methylation: A Potential Strategy for Precision Therapy in PD","volume":"26","author":"Kantor","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Seo, J.H., Shin, J.H., Lee, J., Kim, D., Hwang, H.-Y., Nam, B.-G., Lee, J., Kim, H.H., and Cho, S.-R. (2023). DNA Double-Strand Break-Free CRISPR Interference Delays Huntington\u2019s Disease Progression in Mice. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04829-8"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1038\/s41467-024-50515-6","article-title":"The Therapeutic Implications of All-in-One AAV-Delivered Epigenome-Editing Platform in Neurodegenerative Disorders","volume":"15","author":"Kantor","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s Disease: Pathophysiology and Therapeutic Strategies","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref_139","unstructured":"O\u2019Neal, T.B., Tripathy, K., and Luther, E.E. (2025). Retinitis Pigmentosa. StatPearls, StatPearls Publishing."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","article-title":"In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation","volume":"26","author":"Moreno","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1089\/crispr.2023.0039","article-title":"CRISPRi-Mediated Treatment of Dominant Rhodopsin-Associated Retinitis Pigmentosa","volume":"6","author":"Burnight","year":"2023","journal-title":"Cris. J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.62.12.7","article-title":"Using CRISPR Interference as a Therapeutic Approach to Treat TGF\u03b22-Induced Ocular Hypertension and Glaucoma","volume":"62","author":"Rayana","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"Primary Open-Angle Glaucoma Preferred Practice Pattern\u00ae","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1167\/iovs16-19446","article-title":"HDAC Inhibitor-Mediated Epigenetic Regulation of Glaucoma-Associated TGF\u03b22 in the Trabecular Meshwork","volume":"57","author":"Bermudez","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_145","unstructured":"(2025, June 23). Approved Cellular and Gene Therapy Products; U.S. Food and Drug Administration, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"ref_146","unstructured":"(2025, June 23). Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B\u2014Tune Therapeutics. Available online: https:\/\/tunetx.com\/tune-therapeutics-moves-into-clinical-spotlight-with-tune-401-a-first-in-class-epigenetic-silencer-for-hepatitis-b\/."},{"key":"ref_147","unstructured":"Cosgrove, B. (2025, June 23). Epigenetic Editing for the Treatment of HBV. Available online: https:\/\/tunetx.com\/wp-content\/uploads\/2023\/12\/HEPDART_Dec5_Web.pdf."},{"key":"ref_148","first-page":"178","article-title":"TUNE-401 Is a Novel First-in-Class Epigenetic Silencer Developed for Treatment of Chronic Hepatitis B, with Preclinical Data Showing Strong, Durable, and Precise Transcriptional Repression of HBV DNA","volume":"Volume 80","author":"Cosgrove","year":"2024","journal-title":"The Liver Meeting: 2024 Abstracts"},{"key":"ref_149","unstructured":"Tune Therapeutics, Inc. (2025, June 23). Phase 1b Multicenter, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tune-401 in Participants with Chronic Hepatitis B Infection; Clinical Trial Registration NCT06671093, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06671093."},{"key":"ref_150","unstructured":"(2025, June 23). nChroma Bio Raises $75M to Advance Epigenetic Editing for Hepatitis B and D Cure. Atlas Infectious Disease Practice. Available online: https:\/\/atlasidp.com\/nchroma-bio-raises-75m-to-advance-epigenetic-editing-for-hepatitis-b-and-d-cure\/."},{"key":"ref_151","unstructured":"(2025, June 23). Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio, Securing $75 Million to Accelerate Genetic Medicines. Available online: https:\/\/www.nchromabio.com\/news\/chroma-medicine-and-nvelop-therapeutics-unite-to-form-nchroma-bio-securing-75-million-to-accelerate-genetic-medicines."},{"key":"ref_152","unstructured":"Durrani, J. (2025, June 23). Epigenetic Editors Enter Clinical Trials. Chemistry World. Available online: https:\/\/www.chemistryworld.com\/news\/epigenetic-editors-enter-clinical-trials\/4021267.article."},{"key":"ref_153","unstructured":"Platform (2025, June 23). Epicrispr Biotechnologies. Available online: https:\/\/epicrispr.com\/platform\/."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1016\/j.molcel.2021.08.008","article-title":"Engineered Miniature CRISPR-Cas System for Mammalian Genome Regulation and Editing","volume":"81","author":"Xu","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_155","unstructured":"Adhikari, A., Boregowda, S.V., Zheng, H., Agarwal, V., Norton, A., Silvis, M., Wasala, N., and Collin de l\u2019Hortet, A. (2024, January 7). EPI-321: A Novel Epigenetic Gene Therapy for FSHD Targeting D4Z4 Epigenome. Proceedings of the ASGCT 2024, Baltimore, MD, USA. Available online: https:\/\/epicrispr.com\/wp-content\/uploads\/2024\/05\/EPI-321-A-Novel-Epigenetic-Gene-Therapy-for-FSHD-Targeting-D4Z4-Epigenome.pdf."},{"key":"ref_156","unstructured":"Epicrispr Biotechnologies, Inc. (2025, June 23). A Phase 1\/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-Delivered Epigenetic Editing Therapy in Adult FSHD Patients; Clinical Trial Registration NCT06907875, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06907875."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2402630","DOI":"10.1002\/adfm.202402630","article-title":"Exploring the Potential and Challenges of CRISPR Delivery and Therapeutics for Genetic Disease Treatment","volume":"34","author":"Yang","year":"2024","journal-title":"Adv. Funct. Mater."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Xu, C.L., Ruan, M.Z.C., Mahajan, V.B., and Tsang, S.H. (2019). Viral Delivery Systems for CRISPR. Viruses, 11.","DOI":"10.3390\/v11010028"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Rittiner, J., Cumaran, M., Malhotra, S., and Kantor, B. (2022). Therapeutic Modulation of Gene Expression in the Disease State: Treatment Strategies and Approaches for the Development of next-Generation of the Epigenetic Drugs. Front. Bioeng. Biotechnol., 10.","DOI":"10.3389\/fbioe.2022.1035543"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Dong, W., and Kantor, B. (2021). Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR\/Cas: Current State and Perspectives. Viruses, 13.","DOI":"10.3390\/v13071288"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41417-023-00597-z","article-title":"Viral Vectors and Extracellular Vesicles: Innate Delivery Systems Utilized in CRISPR\/Cas-Mediated Cancer Therapy","volume":"30","author":"Ahmadi","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/JOM.0000000000003166","article-title":"Update on Managing the Risks of Exposure to Lentiviral and Retroviral Vectors","volume":"66","author":"Fujimoto","year":"2024","journal-title":"J. Occup. Environ. Med."},{"key":"ref_163","unstructured":"Guangxun, G. (2025, June 24). A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.; Clinical Trial Registration NCT04037566, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04037566."},{"key":"ref_164","unstructured":"Vor Biopharma (2025, June 24). Phase 1\/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation; Clinical Trial Registration NCT05984199, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05984199."},{"key":"ref_165","unstructured":"Great Ormond Street Hospital for Children NHS Foundation Trust (2025, June 24). Phase 1 Study of Base Edited CAR T Cells Against AML: Deep Conditioning Ahead of Allogeneic Stem Cell Transplantation; Clinical Trial Registration NCT05942599, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05942599."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e3721","DOI":"10.1002\/jgm.3721","article-title":"Gene Therapy Clinical Trials Worldwide to 2023\u2014An Update","volume":"26","author":"Ginn","year":"2024","journal-title":"J. Gene Med."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Leikas, A.J., Yl\u00e4-Herttuala, S., and Hartikainen, J.E.K. (2023). Adenoviral Gene Therapy Vectors in Clinical Use\u2014Basic Aspects with a Special Reference to Replication-Competent Adenovirus Formation and Its Impact on Clinical Safety. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216519"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Anselmo, A.C., and Mitragotri, S. (2021). Viral Vector-based Gene Therapies in the Clinic. Bioeng. Transl. Med., 7.","DOI":"10.1002\/btm2.10258"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Yudaeva, A., Kostyusheva, A., Kachanov, A., Brezgin, S., Ponomareva, N., Parodi, A., Pokrovsky, V.S., Lukashev, A., Chulanov, V., and Kostyushev, D. (2024). Clinical and Translational Landscape of Viral Gene Therapies. Cells, 13.","DOI":"10.3390\/cells13221916"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ijch.201100094","article-title":"Split Inteins: Nature\u2019s Protein Ligases","volume":"51","author":"Shah","year":"2011","journal-title":"Isr. J. Chem."},{"key":"ref_171","unstructured":"Tiffany, M., Frias, S., Andrews, L., Nanjaraj, A., Darst, R., Wist, S., Sajuthi, S., Benda\u00f1a, Y., Tran, H., and Mueller, S. (2025, July 04). Identification and Characterization of STAC-BBB, an Engineered AAV Capsid That Exhibits Widespread Transduction of the Central Nervous System in Cynomolgus Macaques. Available online: https:\/\/www.sangamo.com\/wp-content\/uploads\/2024\/05\/ASGCT-Oral-Presentation-May-8_SGMO_Tiffany_-STAC-BBB-FINAL.pdf."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1089\/hum.2024.035","article-title":"AAV5 Delivery of CRISPR\/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys","volume":"35","author":"Liang","year":"2024","journal-title":"Human. Gene Ther."},{"key":"ref_173","unstructured":"(2025, June 24). Allogeneic TRAC Locus-Inserted CD19-Targeting Synthetic T-Cell Receptor Antigen Receptor (STAR) T Cells for Relapsed\/Refractory B-Cell Non-Hodgkin\u2019s Lymphoma; Clinical Trial Registration NCT06321289, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06321289."},{"key":"ref_174","unstructured":"HuidaGene Therapeutics Co., Ltd. (2025, June 24). A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-Editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor a (HG202) in the Treatment of Neovascular Age-Related Macular Degeneration (nAMD); Clinical Trial Registration NCT06031727, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06031727."},{"key":"ref_175","unstructured":"Cure Rare Disease, Inc. (2025, June 24). Treatment of a Single Patient with CRD-TMH-001; Clinical Trial Registration NCT05514249, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05514249."},{"key":"ref_176","unstructured":"Peking University Third Hospital (2025, June 24). A Single-Arm, Open-Label Exploratory Clinical Study to Assess the Preliminary Safety of the Gene Editing Drug ZVS203e for the Management of Retinitis Pigmentosa Caused by Mutations in the RHO Gene; Clinical Trial Registration NCT05805007, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05805007."},{"key":"ref_177","unstructured":"Excision BioTherapeutics (2025, June 24). Long-Term Follow-Up Study of HIV-1 Infected Adults Exiting a Parent Study Where EBT-101 Was Administered; Clinical Trial Registration NCT05143307, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05143307."},{"key":"ref_178","unstructured":"HuidaGene Therapeutics Co., Ltd. (2025, June 24). An Investigator-Initiated Clinical Study Evaluating the CRISPR-hfCas12Max Gene Editing Therapy in the Treatment of Duchenne Muscular Dystrophy (DMD); Clinical Trial Registration NCT06594094, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06594094."},{"key":"ref_179","unstructured":"HuidaGene Therapeutics Co., Ltd. (2025, June 24). An Open-Label, Multiple-Dose Clinical Study to Evaluating the Safety, Tolerability and Preliminary Efficacy of a Single Intracerebroventricular Injection of HG204 for the Treatment of MECP2 Duplication Syndrome; Clinical Trial Registration NCT06615206, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06615206."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High Levels of AAV Vector Integration into CRISPR-Induced DNA Breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"e20230041","DOI":"10.1002\/INMD.20230041","article-title":"Nucleic Acid Drug and Delivery Techniques for Disease Therapy: Present Situation and Future Prospect","volume":"2","author":"Wang","year":"2024","journal-title":"Interdiscip. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"10059","DOI":"10.1093\/nar\/gkad676","article-title":"Engineered Lentivirus-Derived Nanoparticles (LVNPs) for Delivery of CRISPR\/Cas Ribonucleoprotein Complexes Supporting Base Editing, Prime Editing and in Vivo Gene Modification","volume":"51","author":"Haldrup","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low Immunogenicity of LNP Allows Repeated Administrations of CRISPR-Cas9 mRNA into Skeletal Muscle in Mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/s41563-024-02114-5","article-title":"Blood\u2013Brain-Barrier-Crossing Lipid Nanoparticles for mRNA Delivery to the Central Nervous System","volume":"24","author":"Wang","year":"2025","journal-title":"Nat. Mater."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-Marrow-Homing Lipid Nanoparticles for Genome Editing in Diseased and Malignant Haematopoietic Stem Cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41586-024-08291-2","article-title":"Placenta-Tropic VEGF mRNA Lipid Nanoparticles Ameliorate Murine Pre-Eclampsia","volume":"637","author":"Swingle","year":"2025","journal-title":"Nature"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e2507657","DOI":"10.1002\/adma.202507657","article-title":"Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas","volume":"37","author":"Isaac","year":"2025","journal-title":"Adv. Mater."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.7150\/thno.111200","article-title":"Precision Treatment of Ventilator-Induced Lung Injury through Alveolar Epithelial Cell Targeted Lipid Nanoparticle Delivery","volume":"15","author":"Ding","year":"2025","journal-title":"Theranostics"},{"key":"ref_189","unstructured":"Regeneron Pharmaceuticals (2025, June 24). A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR\/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants with Hemophilia B; Clinical Trial Registration NCT06379789, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06379789."},{"key":"ref_190","unstructured":"Intellia Therapeutics (2025, June 24). Phase 1 Two-Part (Open-Label, Single Ascending Dose (Part 1) and Open-Label, Single Dose Expansion (Part 2)) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) and Patients with Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM); Clinical Trial Registration NCT04601051, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04601051."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"100029","DOI":"10.1016\/j.vesic.2023.100029","article-title":"Guidelines for Clinical Translation and Commercialization of Extracellular Vesicles and Exosomes Based Therapeutics","volume":"2","author":"Cheng","year":"2023","journal-title":"Extracell. Vesicle"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"eabp9435","DOI":"10.1126\/sciadv.abp9435","article-title":"Exosome-Mediated Delivery of Cas9 Ribonucleoprotein Complexes for Tissue-Specific Gene Therapy of Liver Diseases","volume":"8","author":"Wan","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"eadi4830","DOI":"10.1126\/scitranslmed.adi4830","article-title":"Engineered Exosomes with a Photoinducible Protein Delivery System Enable CRISPR-Cas\u2013Based Epigenome Editing in Alzheimer\u2019s Disease","volume":"16","author":"Han","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2312559","DOI":"10.1002\/adma.202312559","article-title":"Injectable Microgels with Hybrid Exosomes of Chondrocyte-Targeted FGF18 Gene-Editing and Self-Renewable Lubrication for Osteoarthritis Therapy","volume":"36","author":"Chen","year":"2024","journal-title":"Adv. Mater."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Saha, T., Saha, R.P., Singh, M.K., Priya, K., Singh, S., Rajeev, M., Bhattacharya, D., Nag, M., and Lahiri, D. (2025). An Overview on In-Vivo Generation of CAR-T Cells Using CRISPR-Loaded Functionalized Nanocarriers for Treating B-Cell Lineage Acute Lymphoblastic Leukemia. Mol. Biol. Rep., 52.","DOI":"10.1007\/s11033-025-10674-1"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Hu, H., Li, S., Zhou, Y., Lv, H., Dong, Z., Wang, Y., Sheng, J., Wang, X., Fan, W., and Xu, W. (2025). A \u2018Two-Missile\u2019 Nanoplatform for Targeting Triple-Negative Breast Cancer: Prodrug Activation and Immune Enhancement. Mater. Today Bio, 32.","DOI":"10.1016\/j.mtbio.2025.101891"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Rauch, B.J., DeLoughery, A., Sper, R., Chen, S., Yunanda, S., Masnaghetti, M., Chai, N., Lin, J.C., Neckelmann, A., and Bjornson, Y. (2025). Single-AAV CRISPR Editing of Skeletal Muscle in Non-Human Primates with NanoCas, an Ultracompact Nuclease. BioRxiv.","DOI":"10.1101\/2025.01.29.635576"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt.2916","article-title":"Genome-Wide Analysis Reveals Characteristics of off-Target Sites Bound by the Cas9 Endonuclease","volume":"32","author":"Kuscu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nbt.2889","article-title":"Genome-Wide Binding of the CRISPR Endonuclease Cas9 in Mammalian Cells","volume":"32","author":"Wu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s13238-016-0360-8","article-title":"An Inducible CRISPR-ON System for Controllable Gene Activation in Human Pluripotent Stem Cells","volume":"8","author":"Guo","year":"2017","journal-title":"Protein Cell"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jgg.2021.06.012","article-title":"Inducible CRISPRa Screen Identifies Putative Enhancers","volume":"48","author":"Dai","year":"2021","journal-title":"J. Genet. Genom."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Petazzi, P., Gutierrez-Ag\u00fcera, F., Roca-Ho, H., Casta\u00f1o, J., Bueno, C., Alvarez, N., Forrester, L.M., Sevilla, A., Fidanza, A., and Menendez, P. (2024). Generation of an Inducible dCas9-SAM Human PSC Line for Endogenous Gene Activation. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1484955"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"eaba5614","DOI":"10.1126\/sciadv.aba5614","article-title":"A Gene Therapy for Inherited Blindness Using dCas9-VPR\u2013Mediated Transcriptional Activation","volume":"6","author":"Splith","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nbt.3149","article-title":"A Split Cas9 Architecture for Inducible Genome Editing and Transcription Modulation","volume":"33","author":"Zetche","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41377-025-01917-8","article-title":"Near-Infrared Light Activatable Chemically Induced CRISPR System","volume":"14","author":"Zhang","year":"2025","journal-title":"Light. Sci. Appl."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00018-025-05786-7","article-title":"Novel Drug-Inducible CRISPRa\/i Systems for Rapid and Reversible Manipulation of Gene Transcription","volume":"82","author":"Sui","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1021\/acschembio.9b01005","article-title":"Heat-Triggered Remote Control of CRISPR-dCas9 for Tunable Transcriptional Modulation","volume":"15","author":"Gamboa","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41592-018-0178-9","article-title":"Engineered Anti-CRISPR Proteins for Optogenetic Control of CRISPR-Cas9","volume":"15","author":"Bubeck","year":"2018","journal-title":"Nat. Methods"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acssynbio.0c00488","article-title":"Engineering an Optogenetic CRISPRi Platform for Improved Chemical Production","volume":"10","author":"Wu","year":"2021","journal-title":"ACS Synth. Biol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1907301","DOI":"10.1002\/smll.201907301","article-title":"Photoactivatable RNA N6-Methyladenosine Editing with CRISPR-Cas13","volume":"16","author":"Zhao","year":"2020","journal-title":"Small"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1021\/acssynbio.3c00035","article-title":"OptoCRISPRi-HD: Engineering a Bacterial Green-Light-Activated CRISPRi System with a High Dynamic Range","volume":"12","author":"Chen","year":"2023","journal-title":"ACS Synth. Biol."},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Huang, H.-C., Wu, L.-F., Liu, K., and Ma, B.-G. (2025). Opto-CRISPR: New Prospects for Gene Editing and Regulation. Trends Biotechnol.","DOI":"10.1016\/j.tibtech.2025.06.018"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41467-019-13765-3","article-title":"Conditional Control of RNA-Guided Nucleic Acid Cleavage and Gene Editing","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"6568","DOI":"10.1038\/s41467-022-34320-7","article-title":"A Comprehensive Bioconductor Ecosystem for the Design of CRISPR Guide RNAs across Nucleases and Technologies","volume":"13","author":"Hoberecht","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of Pre-Existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of Preexisting Adaptive Immunity to Cas9 Proteins in Humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High Prevalence of Streptococcus pyogenes Cas9-Reactive T Cells within the Adult Human Population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.nmd.2023.07.219","article-title":"P309 EPI-321: A Promising Gene Therapy for Facioscapulohumeral Muscular Dystrophy (FSHD) Targeting D4Z4 Epigenome","volume":"33","author":"Adhikari","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41576-025-00873-8","article-title":"Methods and Applications of in Vivo CRISPR Screening","volume":"26","author":"Santinha","year":"2025","journal-title":"Nat. Rev. Genet."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.tibtech.2024.02.007","article-title":"CRISPR Activation Screens: Navigating Technologies and Applications","volume":"42","author":"Clark","year":"2024","journal-title":"Trends Biotechnol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acschembio.7b00657","article-title":"CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine","volume":"13","author":"Kampmann","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/s41588-023-01554-0","article-title":"Transcriptional and Epigenetic Regulators of Human CD8+ T Cell Function Identified through Orthogonal CRISPR Screens","volume":"55","author":"McCutcheon","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"eabj4008","DOI":"10.1126\/science.abj4008","article-title":"CRISPR Activation and Interference Screens Decode Stimulation Responses in Primary Human T Cells","volume":"375","author":"Schmidt","year":"2022","journal-title":"Science"},{"key":"ref_224","doi-asserted-by":"crossref","unstructured":"IGVF Consortium (2024). Deciphering the Impact of Genomic Variation on Function. Nature, 633, 47\u201357.","DOI":"10.1038\/s41586-024-07510-0"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41592-024-02216-7","article-title":"Multicenter Integrated Analysis of Noncoding CRISPRi Screens","volume":"21","author":"Yao","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41588-023-01450-7","article-title":"Dynamic-Network-Guided CRISPRi Screen Identifies CTCF-Loop-Constrained Nonlinear Enhancer-Gene Regulatory Activity during Cell State Transitions","volume":"55","author":"Luo","year":"2023","journal-title":"Nat. Genet."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Gschwind, A.R., Mualim, K.S., Karbalayghareh, A., Sheth, M.U., Dey, K.K., Jagoda, E., Nurtdinov, R.N., Xi, W., Tan, A.S., and Jones, H. (2023). An Encyclopedia of Enhancer-Gene Regulatory Interactions in the Human Genome. bioRxiv.","DOI":"10.1101\/2023.11.09.563812"},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Srivastav, A.K., Mishra, M.K., Lillard, J.W., and Singh, R. (2025). Transforming Pharmacogenomics and CRISPR Gene Editing with the Power of Artificial Intelligence for Precision Medicine. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050555"},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Dixit, S., Kumar, A., Srinivasan, K., Vincent, P.M.D.R., and Ramu Krishnan, N. (2024). Advancing Genome Editing with Artificial Intelligence: Opportunities, Challenges, and Future Directions. Front. Bioeng. Biotechnol., 11.","DOI":"10.3389\/fbioe.2023.1335901"}],"container-title":["DNA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-8856\/5\/4\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:16:32Z","timestamp":1764998192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-8856\/5\/4\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":229,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["dna5040057"],"URL":"https:\/\/doi.org\/10.3390\/dna5040057","relation":{},"ISSN":["2673-8856"],"issn-type":[{"value":"2673-8856","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}